Pfizer Inc. $PFE Shares Sold by Stratos Wealth Partners LTD.

Stratos Wealth Partners LTD. reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 14.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 213,361 shares of the biopharmaceutical company’s stock after selling 35,463 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Pfizer were worth $5,313,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Horizon Financial Services LLC increased its holdings in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares in the last quarter. YANKCOM Partnership acquired a new position in shares of Pfizer during the fourth quarter worth about $28,000. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer during the third quarter worth about $29,000. Howard Hughes Medical Institute purchased a new stake in shares of Pfizer in the second quarter worth about $30,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Pfizer in the second quarter valued at about $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of several analyst reports. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a report on Monday, March 2nd. Guggenheim upped their price target on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Royal Bank Of Canada started coverage on shares of Pfizer in a research note on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price objective on the stock. Bank of America reduced their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Finally, Barclays started coverage on shares of Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $28.19.

Pfizer Trading Up 0.2%

Shares of PFE opened at $28.37 on Monday. The company has a market capitalization of $161.29 billion, a P/E ratio of 20.86 and a beta of 0.43. Pfizer Inc. has a one year low of $20.92 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The stock has a 50-day moving average price of $27.09 and a 200 day moving average price of $25.84.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the previous year, the business earned $0.63 EPS. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.